A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

NCT01986166 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Cobimetinib
DRUG: MEHD7945A

Sponsor

Genentech, Inc.